India to Canada: Paclitaxel Export Trade Route

The India to Canada Paclitaxel corridor is one of India's established pharmaceutical export routes, with 61 shipments documented worth a combined $5.8M USD. The route is dominated by PANACEA BIOTEC PHARMA LIMITED, which alone accounts for roughly 88% of all export value, reflecting the consolidated nature of India's paclitaxel manufacturing sector.

Across 4 active suppliers, the average shipment value stands at $95.6K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 71% of all shipments, consistent with paclitaxel's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 23 days port-to-port. The route has recorded an annual growth rate of 13.4%, placing it at rank #2 among India's top paclitaxel export destinations globally.

On the import side, key buyers of Indian paclitaxel in Canada include APOTEX CORP, APOTEX INC., APOTEX INC and 11 others. APOTEX CORP is the single largest importer with 14 shipments valued at $2.4M USD.

India's paclitaxel exports to Canada are driven primarily by a handful of large-scale manufacturers. PANACEA BIOTEC PHARMA LIMITED with 39 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 4 active exporters signals a competitive but concentrated market — buyers in Canada benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — PANACEA BIOTEC PHARMA LIMITED, INTAS PHARMACEUTICALS LIMITED , INTAS PHARMACEUTICALS LIMITED — together account for 100% of total trade value on this route. The average shipment value of $95.6K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as paclitaxel ( protein-bound particles forinjectable suspension 100 mg) b/n.907024024 m/d.01/2025 e/d.12/2026. and paclitaxel protein bound p article / ods / product / item for, suggesting that buyers in Canada tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, APOTEX CORP is the largest importer with 14 shipments worth $2.4M USD — representing 41% of all paclitaxel imports from India on this route. A total of 14 buyers are active on this corridor.